TP53 and non-small cell lung carcinoma: To determine the effect of SRA737 treatment on “total” DNA strand break damage formation, both NSCLC H23 (TP53 MUT) and A549 (TP53 WT) cells and CRC HT29 (TP53 MUT) and HCT116 (TP53 WT) cells were incubated for 24 h with 0.1 μmol/L, 0.5 μmol/L, 1 μmol/L or 5 μmol/L of SRA737 and then analysed using the ACA.